ESMO 2023: Does stopping VEGFR TKI treatment and continuing immunotherapy influence the survival of patients on combination therapy?
In many countries, combinations of VEGFR TKI anti-cancer mediations plus [...]
ESMO 2023: A new first-line treatment, toripalimab, for advanced kidney cancer
Advanced/metastatic kidney cancer is often treated with a combination of [...]
How long side effects last after treatment with axitinib is stopped
Axitinib is a medicine for the treatment of advanced kidney [...]
Pembrolizumab plus axitinib for metastatic papillary and chromophobe kidney cancer
Non-clear cell kidney cancer is a group of different subtypes [...]
Long-term data support first-line use of avelumab and axitinib for advanced kidney cancer
A recent paper published in The Oncologist has shown that [...]
Does neoadjuvant therapy improve outcomes in localised kidney cancer?
At the 2023 Society of Urologic Oncology (SUO) Annual Meeting, [...]
Ipilimumab-nivolumab and axitinib-pembrolizumab combinations produce similar survival times
When ipilimumab plus nivolumab or axitinib plus pembrolizumab are used [...]
C-reactive protein as a potential biomarker of effectiveness of avelumab plus axitinib in people with advanced kidney cancer
A biomarker is a biological molecule found in blood, other body [...]
Neoadjuvant axitinib may reduce venous tumour thrombus in kidney cancer
Neoadjuvant treatment is medication that is given before surgery to [...]
Neoadjuvant axitinib may enable partial nephrectomy of complex kidney tumours
Just over half of the patients from a phase 2 [...]
